To identify biomarkers associated with BET inhibition induced thrombocytopenia, we initially conducted transcriptional profiling of GATA1, which showed significant (p < 0.05) decreased expression in blood from patients treated with 4.5 mg BMS-986158. The gene discussed is GATA1; the disease is Thrombocytopenia.